Abstract
Hepatocarcinoma is the sixth most common cancer worldwide, but it is considered the second most lethal cancer; only supplanted by lung cancer. The most used prognostic tool in hepatocarcinoma is the Barcelona Clinic Liver Cancer (BCLC) which divides patients considering the tumor size, liver function, performance status, and venous involvement. BCLC A and B patients could be submitted to transarterial chemoembolization (TACE) but the number of procedures acceptable is not known.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
